BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 37256614)

  • 1. Association of Circulating Cardiomyocyte Cell-Free DNA With Cancer Therapy-Related Cardiac Dysfunction in Patients Undergoing Treatment for ERBB2-Positive Breast Cancer.
    Yu AF; Moore ZR; Moskowitz CS; Liu JE; Dang CT; Ramanathan L; Oeffinger KC; Steingart RM; Schmitt AM
    JAMA Cardiol; 2023 Jul; 8(7):697-702. PubMed ID: 37256614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Cardiovascular Magnetic Resonance Tissue Characterization and Cardiotoxicity in Women With Breast Cancer.
    Thavendiranathan P; Shalmon T; Fan CS; Houbois C; Amir E; Thevakumaran Y; Somerset E; Malowany JM; Urzua-Fresno C; Yip P; McIntosh C; Sussman MS; Brezden-Masley C; Yan AT; Koch CA; Spiller N; Abdel-Qadir H; Power C; Hanneman K; Wintersperger BJ
    JAMA Cardiol; 2023 Jun; 8(6):524-534. PubMed ID: 37043251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.
    Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B
    J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.
    van der Voort A; van Ramshorst MS; van Werkhoven ED; Mandjes IA; Kemper I; Vulink AJ; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS
    JAMA Oncol; 2021 Jul; 7(7):978-984. PubMed ID: 34014249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines.
    Thavendiranathan P; Houbois C; Marwick TH; Kei T; Saha S; Runeckles K; Huang F; Shalmon T; Thorpe KE; Pezo RC; Prica A; Maze D; Abdel-Qadir H; Connelly KA; Chan J; Billia F; Power C; Hanneman K; Wintersperger BJ; Brezden-Masley C; Amir E
    Eur Heart J Cardiovasc Pharmacother; 2023 Sep; 9(6):515-525. PubMed ID: 37120736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic and Prognostic Value of Myocardial Work Indices for Identification of Cancer Therapy-Related Cardiotoxicity.
    Calvillo-Argüelles O; Thampinathan B; Somerset E; Shalmon T; Amir E; Steve Fan CP; Moon S; Abdel-Qadir H; Thevakumaran Y; Day J; Woo A; Wintersperger BJ; Marwick TH; Thavendiranathan P
    JACC Cardiovasc Imaging; 2022 Aug; 15(8):1361-1376. PubMed ID: 35926895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
    Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH
    JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction.
    Narayan HK; French B; Khan AM; Plappert T; Hyman D; Bajulaiye A; Domchek S; DeMichele A; Clark A; Matro J; Bradbury A; Fox K; Carver JR; Ky B
    JACC Cardiovasc Imaging; 2016 Oct; 9(10):1131-1141. PubMed ID: 27085442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Combined Echocardiography Approach for the Diagnosis of Cancer Therapy-Related Cardiac Dysfunction in Women With Early-Stage Breast Cancer.
    Esmaeilzadeh M; Urzua Fresno CM; Somerset E; Shalmon T; Amir E; Fan CS; Brezden-Masley C; Thampinathan B; Thevakumaran Y; Yared K; Koch CA; Abdel-Qadir H; Woo A; Yip P; Marwick TH; Chan R; Wintersperger BJ; Thavendiranathan P
    JAMA Cardiol; 2022 Mar; 7(3):330-340. PubMed ID: 35138325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity: A Three Dimentional Echocardiography Study.
    Mohamed AL; El-Abd AA; Mohamed HG; Noufal AM; Hennawy BS
    Curr Probl Cardiol; 2024 Jan; 49(1 Pt C):102130. PubMed ID: 37858847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer.
    Yu AF; Flynn JR; Moskowitz CS; Scott JM; Oeffinger KC; Dang CT; Liu JE; Jones LW; Steingart RM
    JAMA Cardiol; 2020 Mar; 5(3):309-317. PubMed ID: 31939997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superiority of left heart deformation in early anthracycline-related cardiac dysfunction detection.
    Giang M N; Nguyen H H; Vo DT; Ho Huynh Quang T; Phan DTH; Chau NH
    Open Heart; 2023 Nov; 10(2):. PubMed ID: 38011990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
    Henriksen PA; Hall P; MacPherson IR; Joshi SS; Singh T; Maclean M; Lewis S; Rodriguez A; Fletcher A; Everett RJ; Stavert H; Broom A; Eddie L; Primrose L; McVicars H; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Williams MC; Japp A; Payne JR; Newby DE; Mills NL; Oikonomidou O; Lang NN
    Circulation; 2023 Nov; 148(21):1680-1690. PubMed ID: 37746692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
    Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
    Goel S; Liu J; Guo H; Barry W; Bell R; Murray B; Lynch J; Bastick P; Chantrill L; Kiely BE; Abdi E; Rutovitz J; Asghari R; Sullivan A; Harrison M; Kohonen-Corish M; Beith J
    JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis.
    Oikonomou EK; Kokkinidis DG; Kampaktsis PN; Amir EA; Marwick TH; Gupta D; Thavendiranathan P
    JAMA Cardiol; 2019 Oct; 4(10):1007-1018. PubMed ID: 31433450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An artificial intelligence approach for predicting cardiotoxicity in breast cancer patients receiving anthracycline.
    Chang WT; Liu CF; Feng YH; Liao CT; Wang JJ; Chen ZC; Lee HC; Shih JY
    Arch Toxicol; 2022 Oct; 96(10):2731-2737. PubMed ID: 35876889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Early Left Atrial Functional Decline in Predicting Cardiotoxicity in HER2 Positive Breast Cancer Patients Treated With Trastuzumab.
    Bergamini C; Niro L; Springhetti P; Ferri L; Trento L; Minnucci I; Maffeis C; Tafciu E; Rossi A; Fiorio E; Benfari G; Ribichini F
    Cardiovasc Toxicol; 2024 Jun; 24(6):550-562. PubMed ID: 38696070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-dimensional speckle-tracking echocardiography for the global and regional assessments of left ventricle myocardial deformation in breast cancer patients treated with anthracyclines.
    Coutinho Cruz M; Moura Branco L; Portugal G; Galrinho A; Timóteo AT; Rio P; Ilhão Moreira R; Mendonça T; Leal A; Gameiro F; Duarte Oliveira S; Luz R; Cruz Ferreira R
    Clin Res Cardiol; 2020 Jun; 109(6):673-684. PubMed ID: 31559482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.
    Sawaya H; Sebag IA; Plana JC; Januzzi JL; Ky B; Tan TC; Cohen V; Banchs J; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
    Circ Cardiovasc Imaging; 2012 Sep; 5(5):596-603. PubMed ID: 22744937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.